DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enzymes (ALT, AST, GGT) and liver stiffness as measured by Fibroscan in the Phase 1b for NASH patients.

DUR-928 is a endogenous epigenetic regulator.  The compound used the STAM^TM mouse model for non-clinical studies, and data showing the improvement of inflammation and fibrosis in the STAMTM mouse model was presented at AASLD 2017.

For detailed information, see the AASLD 2017 poster.

http://www.durect.com/files/9514/9005/4676/AASLD2017_Emerging_Therapies_STAM.pdf

From the data of liver stiffness measurement by Fibroscan in Phase 1b, it is suggested that DUR-928 improves fibrosis, and data similar to the STAM^TM mouse study results were obtained.

In the future, we believe that further clinical trial results for DUR-928 will provide evidence for the STAM^TM mouse model as a clinically predictive NASH model.